Clinical Trials for Ovarian Cancer

201804169

Cytokine-Induced Depression in Ovarian Cancer: Activation of Kynurenine Pathway Phase N/A Principal Investigator Kuroki, Lindsay Disease Site Corpus Uteri; Other Female Genital; Ovary; Soft Tissue

201806120

Ovation II: Protocol 201-17-201: A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly…

201910142

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Phase III Principal Investigator Thaker, Premal Disease Site Other…

202001099

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Phase II Principal Investigator Mutch, David Disease Site Other Female Genital; Ovary; Soft Tissue Learn more about this study…

202103080

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Other Female Genital; Ovary;…

202103160

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Phase II (Cancer Control) Principal Investigator Thaker, Premal Disease Site Ovary…

202106106

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in…